21st International AIDS Conference (AIDS 2016)


Dual Therapy With Dolutegravir + 3TC Keep Viral Load Undetectable: 48-Week Results From PADDLE Study

August 6, 2016

Updated results from the PADDLE study were a highlight of AIDS 2016 and were presented as an oral late-breaker on the last day.1

This was a small (n=20) single-arm open label study in treatment-naive participants that was notable for reporting at the EACS 2015 conference that rapid viral suppression to <50 copies by week 8 that was maintained to 24 weeks. Although median baseline viral load was low [24,128 copies/mL (IQR: 11,686-36,794), four people were >100,000 copies/mL.2

The results at week 48 were similar, with suppression maintained to <50 copies/mL throughout in 18/20 participants.

Low level detectable viral load was reported at week 36 in one participant who resuppressed without a change in treatment (even though the study protocol recommended changing).

One participant committed suicide linked to "severe stress and emotional trauma" that was not judged related to the study medications.


These results are encouraging for the likelihood of this being a durable option, however small the dataset.


  1. Cahn P et al. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: 48 week results of the PADDLE trial. AIDS 2016, 18-22 July 2016, Durban. Oral late breaker abstract FRAB0104LB. (Abstract) (Slides online thanks to
  2. Figueroa MI et al. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: first results of the PADDLE trial. 15th EACS, Barcelona 2015. Oral abstract LPBS 4/1.

Related Stories

Dolutegravir Is Superior to Boosted Atazanavir in Women in the ARIA Study
Dolutegravir Superior in Women-Only Study

This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.